Literature DB >> 12406905

CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes.

Luisa Granziero1, Paola Circosta, Cristina Scielzo, Elisa Frisaldi, Stefania Stella, Massimo Geuna, Silvia Giordano, Paolo Ghia, Federico Caligaris-Cappio.   

Abstract

Growth and survival of chronic B-cell tumors are favored by the malignant cell's capacity to respond to selected microenvironmental stimuli provided by nontumoral bystander cells. To investigate which mechanisms operate in these crosstalks and whether they are malignancy-related or reproduce the mechanisms used by normal B cells we have studied the expression and functional role of semaphorin CD100 (now called Sema4D) in chronic lymphocytic leukemia (CLL) cells and normal CD5+ B cells. We demonstrate here that (1) leukemic and normal CD5+ B lymphocytes uniformly express CD100; (2) the CD100 high-affinity receptor Plexin-B1 is expressed by bone marrow stromal cells, follicular dendritic cells, and activated T lymphocytes, and is thus available to CD100+ lymphocytes in different specific microenvironments; and (3) upon interaction between CD100 and Plexin-B1 both CLL and normal CD5+ B cells increase their proliferative activity and extend their life span. These findings establish that Plexin-B1 is an easily accessible receptor for CD100 within the immune system. The encounter of CD100+ leukemic cells with Plexin-B1 may promote the proliferation and survival of malignant cells. The crosstalk operated by the CD100/Plexin-B1 interaction is not malignancy related but reproduces a mechanism used by normal CD5+ B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406905     DOI: 10.1182/blood-2002-05-1339

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  Impacts of K562 cells towards activities of Toll-like receptor pathway of human mesenchymal stem cell-bone marrow.

Authors:  Zheng Xu; Jianmin Luo; Lin Yang; Xingzhe Wang; Yuxia Pan; Yintao Shang; Jingci Yang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 2.  Semaphorins: a new class of immunoregulatory molecules.

Authors:  Noriko Takegahara; Atsushi Kumanogoh; Hitoshi Kikutani
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

3.  Bone biopsy derived marrow stromal elements rescue chronic lymphocytic leukemia B-cells from spontaneous and drug induced cell death and facilitates an "angiogenic switch".

Authors:  Neil E Kay; Tait D Shanafelt; Ann K Strege; Yean K Lee; Nancy D Bone; Azra Raza
Journal:  Leuk Res       Date:  2007-01-22       Impact factor: 3.156

Review 4.  Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.

Authors:  Prasanta K Hota; Matthias Buck
Journal:  Cell Mol Life Sci       Date:  2012-06-29       Impact factor: 9.261

Review 5.  Biology and function of neuroimmune semaphorins 4A and 4D.

Authors:  EusebiusHenry Nkyimbeng-Takwi; Svetlana P Chapoval
Journal:  Immunol Res       Date:  2011-05       Impact factor: 2.829

Review 6.  The role of semaphorins in immune responses and autoimmune rheumatic diseases.

Authors:  Masayuki Nishide; Atsushi Kumanogoh
Journal:  Nat Rev Rheumatol       Date:  2017-12-07       Impact factor: 20.543

7.  Hypoxia-inducible factor-1-mediated regulation of semaphorin 4D affects tumor growth and vascularity.

Authors:  Qiangming Sun; Hua Zhou; Nada O Binmadi; John R Basile
Journal:  J Biol Chem       Date:  2009-09-17       Impact factor: 5.157

8.  Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.

Authors:  Rania H Younis; Kyu Lee Han; Tonya J Webb
Journal:  J Immunol       Date:  2016-01-06       Impact factor: 5.422

Review 9.  Semaphorins and their receptors in lung cancer.

Authors:  Vincent A Potiron; Joëlle Roche; Harry A Drabkin
Journal:  Cancer Lett       Date:  2008-07-14       Impact factor: 8.679

10.  Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells.

Authors:  Zhaohui Wei; Naiyao Chen; Hongxing Guo; Xueming Wang; Fangyun Xu; Qian Ren; ShiHong Lu; Bin Liu; Lei Zhang; Hui Zhao
Journal:  J Exp Clin Cancer Res       Date:  2009-11-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.